首页> 外文期刊>Journal of Medicinal Chemistry >Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors
【24h】

Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors

机译:鉴定新型间苯二酚酰胺衍生物作为有效的丙酮酸脱氢酶激酶(PDHK)抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Pyruvate dehydrogenase kinases (PDHKs) promote abnormal respiration in cancer cells. Studies with novel resorcinol amide derivatives based on VER-246608 (6) led to the identification of 19n and 19t containing five-membered heteroaromatic rings as unique structural features. These substances possess single-digit nanomolar activities against PDHKs. 19t exhibits higher potencies against PDHK1/2/4 than does 6 and inhibits only PDHKs among 366 kinases. Moreover, 19g, 19l, and 19s were found to be isotype-selective PDHK inhibitors. Molecular dynamics simulations provide a better understanding of how the heteroaromatic rings affect the activities of 19n and 19t on PDHK1/2/3/4. Moreover, 19n possesses a much higher antiproliferative activity against cancer cells than does 6. We demonstrated that the results of PDH assays better correlate with cellular activities than do those of PDHK kinase assays. Furthermore, 19n induces apoptosis of cancer cells via mitochondrial dysfunction, suppresses tumorigenesis, and displays a synergistic effect on satraplatin suppression of cancer cell proliferation.
机译:丙酮酸脱氢酶激酶(PDHKS)促进癌细胞中的异常呼吸。基于Ver-246608(6)的新型间苯二酚酰胺衍生物的研究导致了含有五元杂芳环的19N和19T,作为独特的结构特征。这些物质具有针对PDHK的单位数纳米摩尔活性。 19T对PDHK1 / 2/4的较高级别而不是6,并仅抑制366激酶之间的PDHK。此外,发现19G,19L和19S是同种型选择性PDHK抑制剂。分子动力学模拟可以更好地理解杂芳环如何影响19n和19t的活动,在PDHK1 / 2/3 / 4上。此外,19N对癌细胞具有比6的更高的抗增殖活性。我们证明了PDH测定的结果与细胞活性更好地相关,而不是PDHK激酶测定。此外,19N通过线粒体功能障碍诱导癌细胞的凋亡,抑制肿瘤发生,对癌细胞增殖的SATRAPLATIN抑制表现出协同作用。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2019年第18期|共19页
  • 作者单位

    KU KIST Grad Sch Converging Sci &

    Technol 145 Anam Ro Seoul 02841 South Korea;

    KU KIST Grad Sch Converging Sci &

    Technol 145 Anam Ro Seoul 02841 South Korea;

    KIST Chem Kinom Res Ctr 5 Hwarangro 14 Gil Seoul 02792 South Korea;

    KIST Chem Kinom Res Ctr 5 Hwarangro 14 Gil Seoul 02792 South Korea;

    Kyungpook Natl Univ Hosp Leading Edge Res Ctr Drug Discovery &

    Dev Diabet Daegu 41404 South Korea;

    Kyungpook Natl Univ Hosp Leading Edge Res Ctr Drug Discovery &

    Dev Diabet Daegu 41404 South Korea;

    Kyungpook Natl Univ Hosp Leading Edge Res Ctr Drug Discovery &

    Dev Diabet Daegu 41404 South Korea;

    Kyungpook Natl Univ Hosp Leading Edge Res Ctr Drug Discovery &

    Dev Diabet Daegu 41404 South Korea;

    Daegu Gyeongbuk Med Innovat Fdn 2387 Dalgubeol Daero Daegu 42019 South Korea;

    KU KIST Grad Sch Converging Sci &

    Technol 145 Anam Ro Seoul 02841 South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号